Trastuzumab biosimilar - STC Biologics

Drug Profile

Trastuzumab biosimilar - STC Biologics

Alternative Names: STC 101

Latest Information Update: 01 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator STC Biologics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 01 Jul 2015 Phase-I clinical trials in Cancer in Europe (SC; IV) (STC Biologics website, June 2015) before July 2015
  • 04 Jun 2015 Trastuzumab biosimilar - STC Biologics is available for licensing as of 04 Jun 2015.
  • 30 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top